Chris Ryan

The EMA’s CHMP has recommended the approval of liso-cel for relapsed/refractory follicular lymphoma after at least 2 prior lines of therapy.

CARGO Therapeutics announced that it will discontinue the phase 2 FIRCE-1 trial evaluating firi-cel in relapsed/refractory large B-cell lymphoma.

The FDA has granted priority review to belzutifan for advanced pheochromocytoma and paraganglioma.

Encorafenib plus cetuximab and mFOLFOX6 improved responses in BRAF V600E–mutated metastatic colorectal cancer.

Neoadjuvant sintilimab plus chemoradiotherapy improved pCR rates in resectable, locally advanced esophageal squamous cell carcinoma.

The FDA approved treosulfan plus fludarabine for alloHSCT conditioning in acute myeloid leukemia or myelodysplastic syndrome.

Nivolumab plus chemotherapy demonstrated long-term survival benefits in advanced gastric, GEJ, or esophageal cancer in China.

The European Commission approved first-line amivantamab plus lazertinib for EGFR-mutated advanced non–small cell lung cancer.

Health Canada approved fruquintinib for select patients with metastatic colorectal cancer.

The development of LAVA-1207 for metastatic castration-resistant prostate cancer has been discontinued.

The FDA approved datopotamab deruxtecan for select unresectable or metastatic, hormone receptor–positive, HER2-negative breast cancer.

Limertinib was approved in China for locally advanced or metastatic non–small cell lung cancer harboring an EGFR T790M mutation.

Obe-cel generated durable remissions in patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated during the FELIX trial.

The xT CDx assay is now available nationwide in the United States for use in solid tumor profiling.

Neal Shore, MD, FACS, discusses implications of data for sasanlimab plus BCG in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Treatment with synthetic hypericin for up to 12 months produced responses in early-stage cutaneous T-cell lymphoma.

Sasanlimab plus BCG improved event-free survival in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Ropeginterferon alfa-2b improved responses in patients with essential thrombocythemia with resistance or intolerance to hydroxyurea.

China’s NMPA has approved zolbetuximab plus chemotherapy for CLDN18.2-positive advanced gastric or GEJ adenocarcinoma.

First-line paromlimab/tuvonralimab plus chemotherapy with or without bevacizumab was active in recurrent/metastatic cervical cancer.

BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.

Satri-cel improved PFS vs investigator’s choice of therapy in pretreated CLDN18.2-positive advanced gastric/GEJ cancer.

Tremelimumab plus paclitaxel induced responses in metastatic urothelial cancer after progression on platinum and an immune checkpoint inhibitor.

The addition of pembrolizumab to radiation did not improve survival in unresected, stage I or II non–small cell lung cancer.

China’s NMPA has granted priority review to the NDA for savolitinib plus osimertinib in pretreated EGFR-mutated advanced NSCLC with MET amplification.

A NDA has been submitted to the FDA seeking the approval of dordaviprone for recurrent H3K27M-mutant diffuse glioma.

After answering her calling for hematology oncology, Margaret A. Shipp, MD, shook up lymphoma research by exploiting the PD-1 pathway to evade immune detection and testing checkpoint inhibitors across this malignancy, among several other achievements.

The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig) for subcutaneous injection across approved adult solid tumor nivolumab (Opdivo) indications.

The FDA has approved tislelizumab plus chemotherapy for unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.

European approval is no longer being sought for Dato-DXd in advanced nonsquamous non–small cell lung cancer.